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TNFaAbstract Background: Despite the fact that Light’s criteria remain the gold standard approach in
differentiating exudates from transudates, several ﬂuid markers have been introduced for establish-
ing the cause of pleural effusion to differentiate types of pleural exudate.
Aim: The aim of this study was to explore means of discriminating between malignant and non
malignant pleural effusions.
Methods: The study conducted on 45 patients (28-males and 17 females) with pleural effusions of
different etiologies. They were classiﬁed according to their ﬁnal diagnosis into four groups: Group I:
10 cases (6 males and 4 females) with tuberculous pleural effusions. Group II: 15 cases (8 males and
7 females) with malignant pleural effusions. Group III: 10 cases (7 males and 3 females) with para-
pneumonic effusion. Group IV: 10 cases (7 males and 3 females) with transudative pleural effusions
included as a control group. The complete biochemical analysis of pleural ﬂuid, pleural ﬂuid
culture, and pathological examination of pleural ﬂuid and tissue was performed. Moreover, quan-
titative measurement of TNF-a in serum and pleural ﬂuid using ELISA was performed.
Results: Levels of TNF-a were signiﬁcantly higher in the pleural ﬂuid of exudative nature
compared to transudative type. There was a signiﬁcant increase in pleural ﬂuid TNF-a level in
non malignant effusions (tuberculous and parapneumonic) compared with malignant effusion. Also
there was a signiﬁcant increase in pleural ﬂuid TNF-a level in tuberculous effusion versus malignant
effusion. These results indicate that TNF-a may be considered a sensitive marker in differentiation
between malignant and non malignant pleural effusions.
Conclusion: Pleural ﬂuid level of TNF-a can be used in differentiating malignant from non
malignant effusion. Also levels of TNF-a in the serum and pleural ﬂuid could be useful as a com-
plementary marker in the differential diagnosis of two most common types of exudates (tuberculous
and malignant).
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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A pleural effusion refers to an abnormal accumulation of ﬂuid
in the pleural cavity, it is often a result of local pleuro-
pulmonary diseases but can also complicate many systemic
pathologies. Pleural effusion develops when the rate of pleural
ﬂuid formation exceeds that of its drainage. Establishing the
underlying cause of pleural effusion is often challenging
because a wide range of local and systemic diseases can lead
to pleural effusion formation. Pleural ﬂuid samples should be
analyzed to determine whether it is a transudate or exudate
[10].
This distinction determines not only the differential diagno-
sis and thus the following therapeutic intervention, but also the
underlying pathophysiologic mechanisms which lead to the
aggregation of ﬂuid in the pleural cavity. Indeed, an exudative
pleural effusion occurs when the permeability of the mesothe-
lial capillary barrier to albumin and other macromolecules is
elevated. In contrast, the presence of a transudate indicates
that the systemic or pulmonary pressures inﬂuencing the for-
mation or reabsorption of pleural ﬂuid are altered [6].
Despite the fact that Light’s criteria remain the gold stan-
dard approach in differentiating exudates from transudates,
several ﬂuid markers have been introduced for diagnostic anal-
ysis. The measurement of pleural ﬂuid interleukin-6, TNFa,
CRP, interferon-gamma, interleukin-1 and immunological
cytokines has been shown to be beneﬁcial to the diagnosis of
exudative pleural effusion [17].
Cytokines are proteins with relatively low molecular
weight that are secreted by cells in response to a variety of
different stimuli and act as key mediators of the host response
to various infections, inﬂammatory, and immunologic chal-
lenges. Cytokines are thought to exert their effects by binding
to speciﬁc receptors on the surface of the cell, although
cytokines may in some instances have direct membrane effects
[14].
Tumor necrosis factor alpha (TNF-a), isolated 30 years
ago, is a multifunctional cytokine playing a key role in apop-
tosis and cell survival as well as in inﬂammation and immunity.
Although named for its antitumor properties, TNF-a has been
implicated in a wide spectrum of other diseases [23].
Tumor necrosis factor-a is a small polypeptide with pleio-
tropic effects on biological and immunological processes. It
is a key cytokine in inﬂammatory reactions, and high levels
of this cytokine in pleural ﬂuid have been detected in several
diseases that cause pleural effusion [13].
Patients and methods
This study was conducted on 45 patients (28-males and 17
females) with pleural effusions of different etiologies, at Benha
University Hospital and Elmehlla chest hospital during the
period from December 2012 till December 2013 after approval
of the study protocol by the Local Ethics Committee and
obtaining fully written informed patients’ consent. The
patients were classiﬁed according to their ﬁnal diagnosis into
four groups: Group I: 10 cases (6 males and 4 females) with
tuberculous pleural effusions. Group II: 15 cases (8 males
and 7 females) with malignant pleural effusions. Group III:
10 cases (7 males and 3 females) with para-pneumonic
effusion. Group IV: 10 cases (7 males and 3 females) withtransudative pleural effusions of congestive heart failure
included as a control group (Table 2).
Exclusion criteria
(1) Any effusion due to undetermined cause or suspected to
have more than one possible cause.
(2) Minimal effusions.
(3) Patients already started any kind of treatmentAll subjects were submitted to the following
All patients were subjected to the following: (1) Full medical
history and clinical examination, routine laboratory investiga-
tions, radiological examination (CXR & CT chest), abdominal
ultrasonography, echocardiography whenever needed. (2)
Tuberculin skin test and Sputum examination for acid fast
bacilli (AFB) by Ziehl–Neelsen stain. 3-ﬁber-optic bron-
choscopy: for patients with suspected bronchogenic carcinoma
where tissue biopsies or bronchoalveolar lavage (BAL) was
sent for histopathological examination. Diagnostic thoraco-
centesis: was done to all patients for physical, chemical,
bacteriological examination and cytological examination.
Quantitative measurement of pleural ﬂuid TNFa using ELISA
technique. Pleural biopsies were taken for all patients in
Groups (I, II, and III) according to the case. Venous blood
samples for quantitative estimation of serum TNFa. Quantita-
tive measurement of TNFa in serum and pleural ﬂuid using
ELISA kit supplied by BOSTER Biological Technology
Catalog No. EK0525.
Statistical analysis
Data collected were analyzed using SPSS version 20 software.
Chi square test (v2), Student’s ‘‘t” test and ANOVA were used
as tests of signiﬁcance. ROC curve was used to detect cutoff
values of TNFa with optimum sensitivity and speciﬁcity.
Stepwise multiple regression analysis was done to detect the
signiﬁcant predictors of TNFa.
Results
The mean age (in years) of Group I was 50.3 + 15.1, Group II
was 67.6 + 10.4, Group III was 46.1 + 11.9 and Group IV
was 59.1 + 10.7 years with male predominance (Table 1).
The mean values of pleural ﬂuid and serum TNF-a levels
were as follows: Group (I) (258.3 + 70.6 and 35.5 + 7.43 pg/
ml), respectively, in Group (II) (50.8 + 18.1 and 26.8
+ 6.31 pg/ml). In Group (III) (88.1 + 35.4 and 26.9
+ 10.1 pg/ml), respectively. While in Group (IV) control, the
mean levels were (21.4 + 8.9 and 18.8 + 7.15 pg/ml), respec-
tively, (Table 4). There was a statistically signiﬁcant difference
in the serum and the pleural ﬂuid mean values of TNF-a
among the four groups (P= 0.001) with a statistically signiﬁ-
cant difference between tuberculous Group (I) which showed
the statistically signiﬁcant highest mean and the three other
groups in which transudative group showed the statistically
signiﬁcant lowest mean (Table 3 and Figs. 1–3).
There was a signiﬁcant difference in the mean levels of
serum and PL TNF-a in exudative effusions (mean was 29.1
Table 1 Descriptive statistics as regards demographic data among the studied groups.
TB Malignant Parapneumonic Transudate f test or X2 P value
Age Range 23–71 53–82 23–64 40–80 2.225 P> 0.05
Mean ± SD 50.3 ± 15.1 67.6 ± 10.4 46.1 ± 11.9 59.1 ± 10.7
n % n % n % n %
Gender Male 6 60 8 53.3 7 70 7 70 1.040 P> 0.05
Female 4 40 7 46.7 3 30 3 30
Table 2 Descriptive statistics as regards type of pleural ﬂuid.
Variable n= 45 % 100.0
Group TB 10 22.2
Malignant 15 33.4
Parapneumonic 10 22.2
Transudate 10 22.2
Type of pleural ﬂuid n %
Exudate 35 77.8
Transudate 10 22.2
Total 45 100
Non-malignant 30 66.7
Malignant 15 33.3
Total 45 100
TNF alpha in differentiation between malignant and non malignant pleural effusion 607+ 8.55 and 120.7 + 99.1 pg/ml, versus transudative effusions
(mean was 18.8 + 7.15 and 21.4 + 8.8 pg/ml)), respectively,
P 6 0.05 and also the ratio (Table 4 and Fig. 4).
There was a signiﬁcant increase in pleural ﬂuid and ratio of
TNF-a levels in the non malignant group versus the malignant
group. (P< 0.003) and no statistically signiﬁcant difference
between the mean values of serum TNF-a of the two groups
(P> 0.05) (Table 5 and Fig. 5).
The efﬁcacy of pleural ﬂuid TNF-a measurement in distin-
guishing between exudative and transudative effusions at a
cutoff value of >20 pg/ml was determined by standard ROC
analysis. The sensitivity of TNF-a in differentiation between
exudative and transudative pleural effusions based on this
optimal cutoff level was 91.2%. The speciﬁcity of exudative
pleural effusion was 84.2% (Table 6 and Fig. 6).
The efﬁcacy of pleural ﬂuid TNF-a measurement in distin-
guishing between non malignant and malignant effusions at a
cutoff value of >78 pg/ml was determined by standard ROC
analysis. The sensitivity and speciﬁcity of TNF-a in differenti-
ation between non malignant and malignant pleural effusionsTable 3 Descriptive statistics as regards the mean TNF-a level in p
TNF-a (pg/ml) TB Malignant
Pleura Range 100.6–338.4 20–78
Mean ± SD 258.3 ± 70.6 50.8 ± 18.1
Serum Range 27.6–48.4 14.3–36.9
Mean ± SD 35.5 ± 7.43 26.8 ± 6.31
PF/S ratio Range 2.86–10.28 1.21–2.32
Mean ± SD 7.20 ± 2.50 1.84 ± 0.37
* Signiﬁcant at P 6 0.05.based on this optimal cutoff level were 91.7% and 91.4%,
respectively (Table 7 and Fig. 7).
The sensitivity and speciﬁcity of pleural TNF-a level in
differentiating between parapneumonic and malignant pleural
effusions at a cutoff point of 37.2 pg/ml were 91.6% and
86.3%, respectively. And between TB and malignant pleural
effusions at a cutoff point of 78 pg/ml were 86.2% and
79.3%, respectively (Table 8 and Figs. 8 and 9).
Discussion
The diagnosis and management of pleural effusion remain a
clinical challenge. Although a variety of simple laboratory tests
are in use, a number of cases remain undiagnosed or the
‘‘diagnosis” is based on clinical evidence alone. This is espe-
cially true regarding the differentiation of exudates of various
causes [25].
A deﬁnitive diagnosis, as is provided by the ﬁnding of
malignant cells or speciﬁc organism in the pleural ﬂuid can
be established in approximately 25% of cases. However, a pre-
sumptive diagnosis, based on the prethoracentesis clinical
impression and pleural effusion analysis, clinical decision-
making information can be gained in over 90% of patients
[5]. The potential utility of many biochemical and immunolog-
ical markers has recently been the subject of research due to
the high costs and the morbidity and mortality risks associated
with the invasive procedures [20].
Tumor necrosis factor-a is a small polypeptide with pleio-
tropic effects on biological and immunological processes. It
is a key cytokine in inﬂammatory reactions, and high levels
of this cytokine in pleural ﬂuid have been detected in several
diseases that cause pleural effusion [13].
The aim of this work was to assess the role of tumor necro-
sis factor-a in differentiation between malignant and non
malignant pleural effusions.leural ﬂuid, in serum and PF/S ratio among the studied groups.
Parapneumonic Transudate f test P value
37.2–142.1 8.3–31.6 9.362 P< 0.001*
88.1 ± 35.4 21.4 ± 8.9
14.8–43.5 6.5–32.1 8.526 P< 0.001*
26.9 ± 10.1 18.8 ± 7.15
0.92–5.51 0.54–1.69 6.325 P< 0.001*
3.50 ± 1.29 1.16 ± 0.33
Figure 1 Mean values of TNF-a level in pleural ﬂuid among the
four groups.
Figure 2 Mean values of TNF-a level in serum among the four
groups.
Figure 3 Mean values of the ratio between pleural and serum
levels of TNF-a among the four groups.
608 H.M. Atef et al.As shown in Table 1 the incidence of tuberculous pleural
effusion in this study was found to be in the ﬁfth decade and
more, this in comparison to the ﬁndings of Hopwell [7] who
found that the incidence of pleural tuberculosis increases with
age between 5 and 45 years. However, more recent studies
reported an older mean age with 10–15% of the patients being
over the age of 70 years [11].
The present study showed the incidence of para-pneumonic
effusion shown in Table 1 was found to be more common in
patients in their 4th decade and more. Light [12] stated thatpleural infection affects patients of all ages but is more
common in the elderly and childhood.
The incidence of tuberculous pleural effusion in the present
study was found to be more in males than in females; this is in
agreement with the ﬁnding of Hopewell [7] who found that
tuberculous pleural effusion is more common in males. How-
ever, Kritski and Fiuza De Melo [9], stated that there was
no difference in the gender distribution in cases of tuberculous
pleural effusion.
The incidence of para-pneumonic effusion was found to be
more in males than in females this is in agreement with the
ﬁndings of Ortqvist et al. [15] who stated that the incidence
of para-pneumonic effusion in males is twice that of females.
Table 3 and Figs. 1–3 show that TNF-a was increased in
pleural ﬂuid of both malignant and inﬂammatory exudates,
compared to transudates. The highest mean values of TNF-
a, were found in tuberculous pleural effusion followed by
parapneumonic pleural effusion then malignant effusion while
that of transudative effusion came last with the lowest mean
values. These ﬁndings were in accordance with that of [8]
who found that pleural ﬂuid TNF-a levels were higher in
tuberculous compared to parapneumonic and malignant
effusions. This may be useful for the differentiation between
tuberculous and malignant effusions.
In Table 4 and Fig. 4, TNF-a was found to be expressed in
higher levels in exudative pleural effusions due to different
causes than those due to transudative pleural effusions in
which they were expressed in lower levels, this is in agreement
with Rezaeetalab et al. [19] who stated the diagnostic value of
TNF-a in the pleural ﬂuid for the discrimination between exu-
dates and transudates. Exudates presented a higher TNF-a
level than transudates, which is synthesized by various acti-
vated phagocytic and non phagocytic cells, and play a key role
in inﬂammatory processes. It is produced during a wide variety
of infections, malignancy and other inﬂammatory conditions.
In Table 5 and Fig. 5, TNF-a was found to have a signiﬁ-
cant increase in the non malignant group versus the malignant
group, this is in agreement with Sen [20] who studied the pre-
dictive value of TNFa and other cytokines in the diagnosis of
malignant pleural effusions and found that TNFa levels were
higher in the benign group.
The results of the study clearly showed that the mean levels
of TNFa were signiﬁcantly greater in the pleural ﬂuid of
patients compared with serum. This was explained by Yenisey
et al. [25] who stated this is probably due to local production of
the cytokine by inﬂammatory cells that have accumulated in
the pleural cavity, although stimulated mesothelial cells may
also contribute to the higher cytokine levels in pleural
exudates.
Smith et al. [21] had explained the signiﬁcantly higher levels
of TNF-a in tuberculous effusions may be a part of a complex
immune response in the pleural space, as TNF-a has both pro-
tective and deleterious roles in tuberculosis. Mycobacterial
products are potent stimuli for TNF-a production by mono-
cytes, providing a plausible explanation for the high levels of
TNF-a in tuberculous effusions this also is in accordance with
[2] and with [1].
The usefulness of pleural ﬂuid TNF-a in the diagnosis and
outcome prediction of pleural TB stated by Wonga et al. [24]
who also found that the percentage change of this cytokine
after 2 weeks of treatment also helps to predict the outcome
of pleural TB.
Table 4 Descriptive statistics as regards the mean levels of TNF-a in pleural ﬂuid, serum and PF/S ratio among exudative and
transudative effusion.
TNF-a (pg/ml) Exudate Transudate f test P value
Pleura Range 20–338 8.30–31.6 5.326 P< 0.001*
Mean + SD 120.7 + 99.1 21.4 + 8.8
Serum Range 14.3–48 6.5–32.1 9.325 P< 0.001*
Mean + SD 29.1 + 8.55 18.8 + 7.15
PF/S ratio Range 0.92–10.28 0.54–1.69 6.332 P< 0.001*
Mean ± SD 3.84 + 2.69 1.16 + 0.33
* Signiﬁcant at p 6 0.05.
Figure 4 Mean levels of TNF-a in pleural ﬂuid, serum and PF/S
ratio in exudative and transudative effusions.
Figure 5 Mean values of TNF-a level in pleural ﬂuid, serum and
PF/S ratio in malignant versus non malignant.
TNF alpha in differentiation between malignant and non malignant pleural effusion 609TNF-a was the single cytokine that signiﬁcantly increased
in the pleural ﬂuid of the TB patients with pulmonary involve-
ment as stated by Antonangelo et al. [3] who found that
TNF-a was signiﬁcantly increased in the pleuropulmonary
tuberculosis patients. This ﬁnding could suggest a more pro-
nounced inﬂammatory response because of the concomitance
of the anatomic sites involved.
TNF-a is expressed in higher values in parapneumonic effu-
sion than those of malignant and transudative pleural
effusions but it is expressed in lower levels than those of tuber-
culous pleural effusions. These results were also in agreement
with the ﬁndings of Daniil et al. [4].
This is also in agreement with Porcel et al. [16] who sug-
gested that pleural TNF-a could be a biochemical marker of
inﬂammation in patients with PPE. Additionally, elevated
levels of pleural TNF-a identiﬁed the subgroup of patientsTable 5 Descriptive statistics as regards the mean levels of TNF-a in
TNF-a (pg/ml) Non-malignant
Pleura Range 8.3–338.4
Mean + SD 122.6 + 19.3
Serum Range 6.5–48.4
Mean + SD 26.8 + 10.5
PF/S ratio Range 0.54–10.28
Mean + SD 3.95 + 2.98
* Signiﬁcant at p 6 0.05.with no purulent-appearing PPE who required invasive man-
agement with tube thoracostomy more reliably than tradi-
tional ﬂuid chemistries and could be considered as an
indicator of poor prognosis in patients with PPE.
High level of TNF-a in malignant pleural effusion stated by
Stathopoulos et al. [22] who also identiﬁed tumor-derived
TNF-a has an important effect of MPE formation and pro-
gression. In addition it provided preclinical evidence for the
efﬁcacy of TNF-a blockade against MPE.
On the contrary, Ragab et al. [18] found that TNFa had a
very limited diagnostic value as it shows a slight elevation
among newly diagnosed lung cancer patients. But they consid-
ered its role in predicting the stage and monitoring lung cancer,
where TNF-a elevation was proportional to the deterioration
of the disease grade and cases with metastasis showed higher
TNF-a than those having no metastasis. TNF-a could be ofpleural ﬂuid, serum and p/s ratio in malignant vs. non malignant.
Malignant f test P value
20–78 5.326 P< 0.003*
50.8 + 18.1
14.3–36.9 2.326 P> 0.05
26.8 + 6.31
1.21–2.32 6.332 P< 0.003*
1.84 + 0.37
Table 6 Sensitivity, speciﬁcity, positive predictive value and negative predictive value of pleural ﬂuid and serum TNF-a for exudative
effusion vs. transudative effusion.
Cutoﬀ (pg/ml) Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%) Accuracy (%)
Exudate vs. transudate
Serum 14.3 94.4 89.3 84.6 91.5 92.3
Pleural 20 91.2 84.2 92.5 85.3 81.4
Figure 6 ROC curve for the performance of TNF-a in the
diagnosis of exudative effusion.
Figure 7 ROC curve for the performance of TNF-a in the
diagnosis of malignant effusion.
610 H.M. Atef et al.great help in the early detection of metastasis in lung cancer,
and could be a valuable factor in following high-risk lung can-
cer patients.
Daniil et al. [4] found that TNF-a concentration levels were
more increased in TPE and stated that combinations of TNF-a
and biological markers as ADA, CRP, CEA, IFN-c, IL-6 and
VEGF concentrations are useful in the discrimination of
exudative pleural effusions.Table 7 Sensitivity, speciﬁcity, positive predictive value and negativ
of malignant effusion.
Cutoﬀ (pg/ml) Sensitivity (%) Speciﬁc
Non malignant vs. Malignant
Serum 27.6 85.7 82.3
Pleural 78 91.7 91.4
Table 8 Diagnostic performance of pleural ﬂuid and serum TNF-a f
malignant vs. TB effusions at the optimal cut-off points of the ROC
Cutoﬀ (pg/ml) Sensitivity (%) Speciﬁc
Parapneumonic vs. Malignant
Serum 14.8 78.6 81.6
Pleural 37.2 91.6 86.3
TB vs. Malignant
Serum 27.6 84.6 90.5
Pleural 78 86.2 79.3In the present study (Table 6 and Fig. 6) a cutoff point of
20 pg/ml pleural ﬂuid TNF-a can be used to differentiate
exudative pleural effusion from transudative pleural effusion
with sensitivity 91.2%, speciﬁcity 84.2%, PPV 92.5%, NPV
85.3%, respectively. Rezaeetalab et al. [19] found that TNFa
levels >12.9 ng/dl are deﬁnitely valuable in differentiating
exudative from transudative pleural effusion. This difference
in values may be due to the sample size.e predictive value of pleural ﬂuid and serum TNF-a in diagnosis
ity (%) PPV (%) NPV (%) Accuracy (%)
80.4 78.3 80.7
86.6 92.5 84.0
or the differential diagnosis of malignant vs. Parapneumonic and
analysis curve.
ity (%) PPV (%) NPV (%) Accuracy (%)
83.6 85.6 84.1
89.3 84.6 90.7
85.6 87.4 91.3
88.3 81.7 76.3
Figure 8 ROC curve of TNF-a for the differentiation of TB vs.
malignant effusions.
Figure 9 ROC curve of TNF-a for the differentiation of
parapneumonic vs. malignant effusions.
TNF alpha in differentiation between malignant and non malignant pleural effusion 611Regarding (Table 7 and Fig. 7), a cutoff point of 78 pg/ml
pleural ﬂuid TNF-a can be used to differentiate malignant
pleural effusion from non malignant pleural effusion with
sensitivity 91.7%, speciﬁcity 91.4%, PPV 86.6%, NPV
92.5%, respectively. This could contribute to the solution to
major problem doctors face every day to differentiate between
malignant and infectious effusions, due to their different
outcome and management.
In Table 8 and Figs. 8 and 9 a cutoff point of 37.2 pg/ml
pleural ﬂuid TNF-a can be used to differentiate parapneu-
monic pleural effusion from malignant pleural effusion with
sensitivity 91.6%, speciﬁcity 86.3%, PPV 84.6%, NPV
92.5%, respectively and a cutoff point of 78 pg/ml pleural ﬂuid
TNF-a can be used to differentiate tuberculous pleural effu-
sion from malignant pleural effusion with sensitivity 86.2%,
speciﬁcity 79.3%, PPV 88.3%, NPV 81.7%, respectively.
These results agree with those of Kiropoulos et al. [8] who
reported that TNF-a presented acceptable performance as a
marker for the differentiation between tuberculous andmalignant effusions, presenting 96% sensitivity, 93.6% speci-
ﬁcity for a cut-off point of 88.1 pg/ml of the ROC analysis
curve. And a cut-off point of 43.9 pg/ml of the ROC analysis
curve for the differentiation between parapneumonic and
malignant effusions with 68.7% sensitivity, 62.5% speciﬁcity.
Conclusion
TNF-a was found in high concentrations in the pleural ﬂuid of
exudative nature compared to transudative pleural effusion
being higher in tuberculous effusion compared with other
types of exudative effusion. TNF-a in the serum and pleural
ﬂuid could be a useful conﬁrmation differential diagnosis of
tuberculous and malignant effusions.
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